[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity
Stoke Therapeutics insider filing: Chief Medical Officer Barry Ticho reported equity awards and acquisitions dated 08/14/2025. The filing shows a direct acquisition of 10,000 shares of common stock at $0, leaving the reporting person with 26,775 shares beneficially owned after the transaction. The filing also reports grants of performance stock units (PSUs) that each convert to one share: an award of 20,000 PSUs granted as restricted stock units upon certification and an award of 10,000 PSUs reported under a separate transaction code. The PSU awards vest in two equal installments, with half vesting on August 14, 2025 and the remainder on August 14, 2026, subject to continued service. All reported derivative holdings and the acquired common shares are shown as direct beneficial ownership.
Comunicazione interna di Stoke Therapeutics: Il Chief Medical Officer Barry Ticho ha segnalato attribuzioni e acquisizioni di azioni in data 14/08/2025. La segnalazione indica un聽acquisto diretto di 10.000 azioni ordinarie a $0, lasciando alla persona che effettua la comunicazione 26.775 azioni possedute beneficiariamente dopo la transazione. La comunicazione riporta inoltre concessioni di performance stock unit (PSU) convertibili ciascuna in una azione: un聽assegnazione di 20.000 PSU che diventeranno restricted stock units al momento della certificazione e un聽ulteriore assegno di 10.000 PSU riportato con un codice di transazione separato. Le PSU maturano in due tranche uguali, con met脿 che matura il 14 agosto 2025 e la restante met脿 il 14 agosto 2026, subordinatamente al proseguimento del rapporto di servizio. Tutte le posizioni in derivati segnalate e le azioni ordinarie acquisite sono indicate come possesso beneficiario diretto.
Presentaci贸n interna de Stoke Therapeutics: El Chief Medical Officer Barry Ticho inform贸 adjudicaciones y adquisiciones de acciones con fecha 14/08/2025. La presentaci贸n muestra una adquisici贸n directa de 10.000 acciones ordinarias a $0, dejando a la persona informante con 26.775 acciones de propiedad beneficiaria tras la transacci贸n. La presentaci贸n tambi茅n informa concesiones de performance stock units (PSUs) que cada una se convierte en una acci贸n: una adjudicaci贸n de 20.000 PSU que se otorgar谩n como restricted stock units al certificarse y una adjudicaci贸n adicional de 10.000 PSU reportada bajo un c贸digo de transacci贸n separado. Las PSUs consolidan en dos cuotas iguales, con la mitad que vence el 14 de agosto de 2025 y el resto el 14 de agosto de 2026, sujeto a la continuidad del servicio. Todas las tenencias en derivados informadas y las acciones ordinarias adquiridas se muestran como propiedad beneficiaria directa.
Stoke Therapeutics 雮措秬 瓿奠嫓: 斓滉碃鞚橅暀毂呾瀯鞛�(Chief Medical Officer) 氚半Μ 韹办磮(Barry Ticho)臧� 2025-08-14鞛� 歆�攵� 靾橃棳 氚� 旆摑鞚� 氤搓碃頄堨姷雼堧嫟. 瓿奠嫓鞐愲姅 氤错喌欤� 10,000欤茧ゼ 欤茧嫻 $0鞐� 歆侅爲 旆摑頃� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨溂氅�, 頃措嫻 氤搓碃鞚胳潃 瓯半灅 頉� 26,775欤检潣 鞁れ 氤挫湢鞛愲ゼ 鞙犾頃橁矊 霅╇媹雼�. 瓿奠嫓鞐愲姅 霕愴暅 臧侁皝 1欤茧 鞝勴櫂霅橂姅 韻柬彫毹检姢 鞀ろ啞 鞙犽嫑(PSU) 靾橃棳 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟: 鞚胳 鞁� 鞝滍暅 欤检嫕 雼渼(restricted stock units)搿� 鞝勴櫂霅橂姅 20,000 PSU鞕� 氤勲弰鞚� 瓯半灅 旖旊摐搿� 氤搓碃霅� 10,000 PSU 靾橃棳臧� 鞛堨姷雼堧嫟. PSU電� 鞝堧皹鞌� 霊� 氩堨棎 瓯胳硱 氩犾姢韺呺悩氅�, 鞝堧皹鞚� 2025雲� 8鞗� 14鞚�鞐�, 雮橂ǜ歆� 鞝堧皹鞚� 2026雲� 8鞗� 14鞚�鞐� 氩犾姢韸鸽悩氅� 瓿勳啀 攴茧毳� 臁瓣贝鞙茧 頃╇媹雼�. 氤搓碃霅� 氇摖 韺岇儩靸來拡 氤挫湢 氚� 旆摑霅� 氤错喌欤茧姅 歆侅爲 鞁れ 氤挫湢搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟.
D茅claration d'initi茅 de Stoke Therapeutics : Le Chief Medical Officer Barry Ticho a d茅clar茅 des attributions et acquisitions d'actions dat茅es du 14/08/2025. La d茅claration indique une acquisition directe de 10 000 actions ordinaires 脿 $0, laissant la personne d茅clarante avec 26 775 actions d茅tenues b茅n茅ficiairement apr猫s la transaction. La d茅claration signale 茅galement des octrois de performance stock units (PSU) convertibles chacun en une action : une attribution de 20 000 PSU accord茅es sous forme de restricted stock units lors de la certification et une attribution suppl茅mentaire de 10 000 PSU rapport茅e sous un code de transaction distinct. Les PSU acqui猫rent en deux versements 茅gaux, la moiti茅 arrivant 脿 茅ch茅ance le 14 ao没t 2025 et le reste le 14 ao没t 2026, sous r茅serve de la poursuite du service. Toutes les positions en d茅riv茅s d茅clar茅es et les actions ordinaires acquises sont indiqu茅es comme d茅tention b茅n茅ficiaire directe.
Insider-Meldung von Stoke Therapeutics: Chief Medical Officer Barry Ticho meldete Aktienzuteilungen und -erwerbe datiert auf den 14.08.2025. Die Meldung zeigt einen direkten Erwerb von 10.000 Stammaktien zu $0, wodurch die meldende Person nach der Transaktion 26.775 Aktien wirtschaftlich besitzt. Ebenfalls gemeldet wurden Zuteilungen von Performance Stock Units (PSUs), die jeweils in eine Aktie umgewandelt werden: eine Auszeichnung von 20.000 PSUs, die bei Zertifizierung in Restricted Stock Units 眉bergehen, sowie eine weitere Zuteilung von 10.000 PSUs unter einem separaten Transaktionscode. Die PSU-Zuteilungen vesten in zwei gleichen Tranchen, wobei die H盲lfte am 14. August 2025 und der Rest am 14. August 2026 f盲llig wird, vorbehaltlich fortgesetzter Dienstzeit. Alle gemeldeten Derivatpositionen und die erworbenen Stammaktien werden als direkte wirtschaftliche Beteiligung ausgewiesen.
- Executive alignment: CMO received 30,000 PSUs that convert to common shares, aligning compensation with company performance and retention.
- Increased insider ownership: Direct acquisition of 10,000 common shares resulted in 26,775 shares beneficially owned after the transaction.
- Clear vesting schedule: PSUs vest in two equal tranches on Aug 14, 2025 and Aug 14, 2026, subject to service and certification.
- None.
Insights
TL;DR: Routine executive equity grants and a nominal share acquisition increase insider alignment without immediate cash consideration.
The filing documents a standard equity-compensation event: a direct acquisition of 10,000 common shares at no cash price and performance-based restricted stock unit grants totaling 30,000 PSUs that convert one-for-one into shares. Vesting is time- and performance-contingent, with half of each award vesting on August 14, 2025 and the remainder on August 14, 2026, contingent on certification and continued service. For investors, this represents management alignment with shareholder outcomes but is a common compensation mechanism rather than a standalone material corporate event.
TL;DR: Compensation committee-certified PSUs and a direct share award reflect standard executive remuneration and retention practices.
The disclosure specifies that one PSU equals one share and that the 20,000-unit award was granted upon certification of performance conditions by the compensation committee. Vesting is split over two annual dates, tying retention to continued service. The direct beneficial ownership figures are clearly stated, and there is no indication of indirect holdings or related-party arrangements. This is a routine governance disclosure signaling incentive alignment rather than an extraordinary governance event.
Comunicazione interna di Stoke Therapeutics: Il Chief Medical Officer Barry Ticho ha segnalato attribuzioni e acquisizioni di azioni in data 14/08/2025. La segnalazione indica un聽acquisto diretto di 10.000 azioni ordinarie a $0, lasciando alla persona che effettua la comunicazione 26.775 azioni possedute beneficiariamente dopo la transazione. La comunicazione riporta inoltre concessioni di performance stock unit (PSU) convertibili ciascuna in una azione: un聽assegnazione di 20.000 PSU che diventeranno restricted stock units al momento della certificazione e un聽ulteriore assegno di 10.000 PSU riportato con un codice di transazione separato. Le PSU maturano in due tranche uguali, con met脿 che matura il 14 agosto 2025 e la restante met脿 il 14 agosto 2026, subordinatamente al proseguimento del rapporto di servizio. Tutte le posizioni in derivati segnalate e le azioni ordinarie acquisite sono indicate come possesso beneficiario diretto.
Presentaci贸n interna de Stoke Therapeutics: El Chief Medical Officer Barry Ticho inform贸 adjudicaciones y adquisiciones de acciones con fecha 14/08/2025. La presentaci贸n muestra una adquisici贸n directa de 10.000 acciones ordinarias a $0, dejando a la persona informante con 26.775 acciones de propiedad beneficiaria tras la transacci贸n. La presentaci贸n tambi茅n informa concesiones de performance stock units (PSUs) que cada una se convierte en una acci贸n: una adjudicaci贸n de 20.000 PSU que se otorgar谩n como restricted stock units al certificarse y una adjudicaci贸n adicional de 10.000 PSU reportada bajo un c贸digo de transacci贸n separado. Las PSUs consolidan en dos cuotas iguales, con la mitad que vence el 14 de agosto de 2025 y el resto el 14 de agosto de 2026, sujeto a la continuidad del servicio. Todas las tenencias en derivados informadas y las acciones ordinarias adquiridas se muestran como propiedad beneficiaria directa.
Stoke Therapeutics 雮措秬 瓿奠嫓: 斓滉碃鞚橅暀毂呾瀯鞛�(Chief Medical Officer) 氚半Μ 韹办磮(Barry Ticho)臧� 2025-08-14鞛� 歆�攵� 靾橃棳 氚� 旆摑鞚� 氤搓碃頄堨姷雼堧嫟. 瓿奠嫓鞐愲姅 氤错喌欤� 10,000欤茧ゼ 欤茧嫻 $0鞐� 歆侅爲 旆摑頃� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨溂氅�, 頃措嫻 氤搓碃鞚胳潃 瓯半灅 頉� 26,775欤检潣 鞁れ 氤挫湢鞛愲ゼ 鞙犾頃橁矊 霅╇媹雼�. 瓿奠嫓鞐愲姅 霕愴暅 臧侁皝 1欤茧 鞝勴櫂霅橂姅 韻柬彫毹检姢 鞀ろ啞 鞙犽嫑(PSU) 靾橃棳 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟: 鞚胳 鞁� 鞝滍暅 欤检嫕 雼渼(restricted stock units)搿� 鞝勴櫂霅橂姅 20,000 PSU鞕� 氤勲弰鞚� 瓯半灅 旖旊摐搿� 氤搓碃霅� 10,000 PSU 靾橃棳臧� 鞛堨姷雼堧嫟. PSU電� 鞝堧皹鞌� 霊� 氩堨棎 瓯胳硱 氩犾姢韺呺悩氅�, 鞝堧皹鞚� 2025雲� 8鞗� 14鞚�鞐�, 雮橂ǜ歆� 鞝堧皹鞚� 2026雲� 8鞗� 14鞚�鞐� 氩犾姢韸鸽悩氅� 瓿勳啀 攴茧毳� 臁瓣贝鞙茧 頃╇媹雼�. 氤搓碃霅� 氇摖 韺岇儩靸來拡 氤挫湢 氚� 旆摑霅� 氤错喌欤茧姅 歆侅爲 鞁れ 氤挫湢搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟.
D茅claration d'initi茅 de Stoke Therapeutics : Le Chief Medical Officer Barry Ticho a d茅clar茅 des attributions et acquisitions d'actions dat茅es du 14/08/2025. La d茅claration indique une acquisition directe de 10 000 actions ordinaires 脿 $0, laissant la personne d茅clarante avec 26 775 actions d茅tenues b茅n茅ficiairement apr猫s la transaction. La d茅claration signale 茅galement des octrois de performance stock units (PSU) convertibles chacun en une action : une attribution de 20 000 PSU accord茅es sous forme de restricted stock units lors de la certification et une attribution suppl茅mentaire de 10 000 PSU rapport茅e sous un code de transaction distinct. Les PSU acqui猫rent en deux versements 茅gaux, la moiti茅 arrivant 脿 茅ch茅ance le 14 ao没t 2025 et le reste le 14 ao没t 2026, sous r茅serve de la poursuite du service. Toutes les positions en d茅riv茅s d茅clar茅es et les actions ordinaires acquises sont indiqu茅es comme d茅tention b茅n茅ficiaire directe.
Insider-Meldung von Stoke Therapeutics: Chief Medical Officer Barry Ticho meldete Aktienzuteilungen und -erwerbe datiert auf den 14.08.2025. Die Meldung zeigt einen direkten Erwerb von 10.000 Stammaktien zu $0, wodurch die meldende Person nach der Transaktion 26.775 Aktien wirtschaftlich besitzt. Ebenfalls gemeldet wurden Zuteilungen von Performance Stock Units (PSUs), die jeweils in eine Aktie umgewandelt werden: eine Auszeichnung von 20.000 PSUs, die bei Zertifizierung in Restricted Stock Units 眉bergehen, sowie eine weitere Zuteilung von 10.000 PSUs unter einem separaten Transaktionscode. Die PSU-Zuteilungen vesten in zwei gleichen Tranchen, wobei die H盲lfte am 14. August 2025 und der Rest am 14. August 2026 f盲llig wird, vorbehaltlich fortgesetzter Dienstzeit. Alle gemeldeten Derivatpositionen und die erworbenen Stammaktien werden als direkte wirtschaftliche Beteiligung ausgewiesen.
FAQ
Who filed the Form 4 for STOK and what is their role?
What transactions were reported on the 08/14/2025 STOK filing?
How many shares does the reporting person beneficially own after the transaction?
What are the vesting terms for the performance stock units?
Did the filing indicate any indirect beneficial ownership or third-party arrangements?
